Published in Clinical Trials Week, November 29th, 2004
William Sandborn, MD, Division of Gastroenterology and Hepatology. Mayo Clinic, Rochester, Minnesota, said if the treatment receives approval from the U.S. Food and Drug Administration (FDA), it will provide a new treatment for patients who need higher doses of the drug mesalamine, instead of resorting to steroid therapies, which sometimes have harsh side effects.
The study, sponsored by Procter &...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.